Characteristics of the 321 MZL patients who received immediate systemic therapy (study population) and comparison with MZL patients enrolled in the NF10 who did not receive immediate therapy
| Factor . | Missing . | Untreated, n (%) . | Treated, n (%) . | P . |
|---|---|---|---|---|
| Total | 286 | 321 | ||
| MZL* | ||||
| ENMZL | — | 96 (34) | 146 (46) | <.001 |
| SMZL | — | 122 (43) | 84 (26) | |
| NMZL | — | 30 (10) | 32 (10) | |
| Diss-MZL | — | 38 (13) | 59 (18) | |
| Age >60 y | — | 203 (71) | 202 (62) | .039 |
| ECOG PS >1 | 3 | 8 (3) | 21 (7) | .036 |
| Symptoms, B | 3 | 19 (7) | 66 (21) | <.001 |
| Hb <12 g/dL | 3 | 73 (26) | 129 (40) | <.001 |
| Platelets <150 × 109/L | 5 | 97 (34) | 90 (28) | .094 |
| LDH > UNL | 30 | 61 (23) | 96 (31) | .049 |
| B2M > UNL | 17 | 96 (41) | 156 (60) | <.001 |
| LN size >6 cm | 61 | 8 (3) | 34 (11) | <.001 |
| Albumin <3.5 g/dL | 74 | 15 (8) | 51 (22) | <.001 |
| HBV serology, + | 12 | 23 (8) | 25 (9) | .88 |
| HCV serology, + | 27 | 35 (12) | 67 (21) | .012 |
| Treatment | ||||
| Watch and wait | 7 | 286 (100) | — | |
| Alk-Mono | — | — | 16 (5) | |
| R-Mono | — | — | 30 (9) | |
| R-Alkylating | — | — | 83 (26) | |
| R-CHOP | — | — | 48 (15) | |
| R-Bendamustine | — | — | 112 (35) | |
| R-Fludarabine | — | — | 3 (1) | |
| Other | — | — | 21 (6) |
| Factor . | Missing . | Untreated, n (%) . | Treated, n (%) . | P . |
|---|---|---|---|---|
| Total | 286 | 321 | ||
| MZL* | ||||
| ENMZL | — | 96 (34) | 146 (46) | <.001 |
| SMZL | — | 122 (43) | 84 (26) | |
| NMZL | — | 30 (10) | 32 (10) | |
| Diss-MZL | — | 38 (13) | 59 (18) | |
| Age >60 y | — | 203 (71) | 202 (62) | .039 |
| ECOG PS >1 | 3 | 8 (3) | 21 (7) | .036 |
| Symptoms, B | 3 | 19 (7) | 66 (21) | <.001 |
| Hb <12 g/dL | 3 | 73 (26) | 129 (40) | <.001 |
| Platelets <150 × 109/L | 5 | 97 (34) | 90 (28) | .094 |
| LDH > UNL | 30 | 61 (23) | 96 (31) | .049 |
| B2M > UNL | 17 | 96 (41) | 156 (60) | <.001 |
| LN size >6 cm | 61 | 8 (3) | 34 (11) | <.001 |
| Albumin <3.5 g/dL | 74 | 15 (8) | 51 (22) | <.001 |
| HBV serology, + | 12 | 23 (8) | 25 (9) | .88 |
| HCV serology, + | 27 | 35 (12) | 67 (21) | .012 |
| Treatment | ||||
| Watch and wait | 7 | 286 (100) | — | |
| Alk-Mono | — | — | 16 (5) | |
| R-Mono | — | — | 30 (9) | |
| R-Alkylating | — | — | 83 (26) | |
| R-CHOP | — | — | 48 (15) | |
| R-Bendamustine | — | — | 112 (35) | |
| R-Fludarabine | — | — | 3 (1) | |
| Other | — | — | 21 (6) |
—, not applicable; Alk-Mono, monotherapy with alkylating agents; B2M, β2-microglobulin; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; Diss-MZL, disseminated MZL; ECOG PS, Eastern Cooperative Oncology Group performance status; Hb, hemoglobin; HBV, hepatitis B virus; HCV, hepatitis C virus; LDH, lactate dehydrogenase; LN, lymph node; R, rituximab.
Eligible patients were classified as SMZL, ENMZL, and NMZL according to local pathologic diagnosis. Patients with histologic features consistent with MZL with concomitant involvement of the marrow and/or spleen and/or lymph nodes and/or extranodal sites but lacking the diagnostic features of SMZL, NMZL, or ENMZL were categorized as Diss-MZL.